Initially approved for R/R B-ALL in pediatric and young adult patients in April 2017 in the USA [2, 3], Tisagenlecleucel (Tisa-cel) is an autologous CD19-directed T-cell immunotherapy that has been widely used in many countries. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.